• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochemical Pharmacology >The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis
【24h】

The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis

机译：靶向FCR作为类风湿性关节炎新型治疗策略的前景

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial membrane hyperplasia, infiltration of inflammatory cells and bone tissue destruction. Although there have been many measures taken for RA therapy in recent years, they are not sufficiently safe or effective. Thus, it is very important to develop new drugs and slow down damage to other healthy organs in the case of RA. Lately, immunoglobulin Fc receptors (FcRs), such as the IgG Fc receptor (Fc gamma R), IgA Fc receptor (Fc alpha R), and IgD Fc receptor (Fc delta R), have been found to be involved in inducing or suppressing arthritis. FcRs interacting with immune complexes (ICs) are a key factor in the etiopathogenesis of RA. Therefore, an increasing number of methods for the targeted treatment of RA with FcRs are emerging, such as recombinant soluble Fc gamma Rs, recombinant multimeric Fc fragments and monoclonal antibodies, and have been demonstrated to significantly improve RA symptoms. Simultaneously, certain kinases involved in the downstream signaling of FcRs can also be a target for the treatment of RA, such as Syk and Btk inhibitors. An overview of these FcRs is provided in this review, including a description of FcRrelated functions, signaling pathways, and potential FcR-targeting molecules for RA therapy. To date, the initial results of those developed FcR-targeting molecules have been promising. With this, FcRs might offer a better alternative to RA medication. Additionally, further pharmacological characterization and a better understanding of the unique mechanisms of FcR-targeting molecules are necessary.
机译：类风湿性关节炎（RA）是一种慢性全身自身免疫疾病，其特征在于滑膜增生，炎症细胞浸润和骨组织破坏。虽然近年来Ra治疗采取了许多措施，但它们并不充分安全或有效。因此，在RA的情况下，为其他健康器官发育新的药物并减慢伤害是非常重要的。最近，已发现免疫球蛋白Fc受体（FCRS），例如IgG Fc受体（Fcγr），IgA Fc受体（FcαR）和IgD Fc受体（Fc Delta R）参与诱导或抑制关节炎。与免疫复合物相互作用的FCR是RA的硫代病变的关键因素。因此，越来越多的用于具有FCR的RA治疗的方法是出现的，例如重组可溶性FcγRS，重组多聚体Fc碎片和单克隆抗体，并且已被证明以显着改善Ra症状。同时，参与FCR的下游信号传导的某些激酶也可以是治疗RA的靶标，例如SYK和BTK抑制剂。本次综述中提供了这些FCR的概述，包括用于RA治疗的函数，信号通路和潜在的FCR靶向分子的描述。迄今为止，那些开发的FCR靶向分子的初始结果一直很有前途。由此，FCR可能会提供更好的替代RA药物。另外，需要进一步的药理学表征和更好地理解FCR靶向分子的独特机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号